Related Experiment Video
Updated: Jun 27, 2025
10:17
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
524
Programmed Ventricular Stimulation: Risk Stratification and Guiding Antiarrhythmic Therapies
Timothy M Markman1, Francis E Marchlinski1, David J Callans1
1Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
JACC. Clinical Electrophysiology
|April 25, 2024
Summary
Programmed ventricular stimulation (PVS) aids risk stratification for cardiomyopathies and guides antiarrhythmic therapy, including catheter ablation. Optimizing PVS protocols enhances its accuracy in predicting sudden cardiac death and assessing treatment effectiveness.
Area of Science:
- Cardiology
- Electrophysiology
- Cardiac Arrhythmias
Background:
- Programmed ventricular stimulation (PVS) is crucial for inducing ventricular tachycardia (VT) in patients with cardiomyopathies.
- It aids in risk stratification for sudden cardiac death and evaluates antiarrhythmic therapy efficacy, particularly catheter ablation.
- PVS procedural parameters and positive result definitions influence test sensitivity and specificity.
Purpose of the Study:
- To review the history and current role of PVS in risk stratification for various patient populations.
- To propose future research directions for optimizing PVS sensitivity and specificity.
- To discuss PVS application during and after catheter ablation and its role in guiding management decisions.
Main Methods:
- Review of historical data and current literature on programmed ventricular stimulation (PVS).
- Analysis of procedural modifications (pacing cycle lengths, extrastimuli, locations) and definition of positive results.
- Evaluation of PVS in ischemic and nonischemic cardiomyopathies, sudden cardiac death risk, and antiarrhythmic therapy assessment.
Main Results:
- PVS is a valuable tool for risk stratification and assessing therapeutic efficacy in cardiomyopathies.
- Modifying PVS protocols can alter test sensitivity and specificity for VT induction.
- Noninvasive programmed stimulation can predict recurrent VT and inform management strategies.
Conclusions:
- PVS plays a significant role in managing patients with ventricular arrhythmias and cardiomyopathies.
- Optimizing PVS protocols and definitions is essential for accurate risk stratification and treatment assessment.
- Future research should focus on refining PVS strategies to maximize its clinical utility.
Related Concept Videos
01:28Disturbances in Heart Rhythm
945
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
945
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:28Mechanism of Cardiac Arrhythmias
917
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
917
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832